학술논문
Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease
Document Type
Article
Author
Source
In Alzheimer's & Dementia: Translational Research & Clinical Interventions January 2016 2(1):1-12
Subject
Language
ISSN
2352-8737